Our Team

Dr. Tongde Wu joined Biologics Consulting Group in January 2025, bringing a strong foundation in Pharmacology and Toxicology. Prior to this, she was a key member of Eliquent Life Sciences from 2021 to 2024 and served as a Research Assistant Professor at North Carolina Central University. Dr. Wu earned her Ph.D. in Pharmacology and Toxicology from the University of Arizona, where she worked as a mechanistic toxicologist. She led research that uncovered a novel mechanism of CCl4-induced hepatotoxicity. Afterward, she completed postdoctoral training in Pulmonary Physiology at the University of North Carolina at Chapel Hill, focusing on the interaction between environmental toxicants and respiratory systems. She continued her research in pulmonary toxicology at North Carolina Central University, leading a team that demonstrated how house dust mites (HDM) exacerbate Th2 inflammation in the asthmatic airway through proteolytic activity. Before joining Biologics Consulting Group, Dr. Wu worked as a senior nonclinical consultant, demonstrating comprehensive regulatory proficiency in the development of monoclonal antibodies, small molecule drugs, and gene and cell therapies, across therapeutic areas such as solid tumors, infectious diseases, and metabolic diseases. As a subject matter expert in pharm and tox, she consistently applied her deep scientific understanding of nonclinical drug development, working with colleagues and clients to address deficiencies in nonclinical study designs and enhance programs for regulatory success. Dr. Wu played a key role in conducting nonclinical gap assessments, reviewing study protocols, study reports, and refining regulatory submissions. At Eliquent Life Sciences, she contributed to the preparation of over a dozen IND applications and PIND meetings, advancing numerous development programs. She also supported clients in obtaining Orphan Drug Designation (ODD), Fast Track (FT), and Regenerative Advanced Medicine Therapy (RAMT) designations. Dr. Wu became an invaluable asset to both Eliquent Life Sciences and its clients, recognized for her attention to detail, strong communication, and regulatory expertise. She has been a DABT since 2022 and earned her RAC in 2023. Dr. Wu earned a B.S. in Biotechnology from Anhui Medical University in Hefei, Anhui, China, and an M.S. in Biochemistry and Molecular Biology from Fudan University in Shanghai, China. She is proficient in Microsoft Office Suite, Adobe Photoshop, GraphPad Prism, and Vector NTI, and is bilingual in English and Chinese Mandarin. Dr. Wu also holds a US patent for peptide inhibitors of calcium channels (US10894811B2).